Novel Approaches for Oral Insulin Delivery - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Novel Approaches for Oral Insulin Delivery
The authors review various oral drug delivery systems that have been explored to increase patient compliance for insulin.

Pharmaceutical Technology
Volume 33, Issue 7

An aqueous nanoparticulate delivery system containing oppositely charged polymers polyethylenimine (PEI) and DS with zinc as a stabilizer was developed by Tiyaboonchai et al. (43). The pH of PEI solutions, the weight ratio of the two polymers, and zinc sulfate concentrations affected the particle size of the nanoparticles. Spherical particles of 250 nm mean diameter with a zeta potential of approximately +30 mV were produced under optimal conditions. Insulin could be loaded up to 90% in these nanoparticles. Circular dichroism spectra showed no significant conformational changes compared with free insulin under optimized formulation conditions. In contrast to rapid release of insulin in vitro, the hypoglycemic activity in streptozotocin-induced diabetic rats was prolonged. This system offered a number of advantages, including ease of manufacturing under mild preparation conditions, completely aqueous processing conditions, use of biocompatible polymers, ability to control particle size, a high level of drug entrapment, and an ability to preserve secondary structure and biological activity of protein.

Simon et al. prepared nanosized insulin-complexes based on amine modified comb-like polyesters (44). Protection of insulin in nanocomplexes from enzymatic degradation was investigated. The interaction with enterocyte-like Caco-2 cells in terms of cytotoxicity, transport through and uptake in the cell layers was evaluated by measuring transepithelial electrical resistance (TEER), release of lactate dehydrogenase (LDH), and insulin transport. The protection capacity of the nanocomplexes and their interaction with Caco-2 cells varied strongly as a function of lactide-grafting (hydrophobicity). With increasing lactide-grafting (P(26)P(26)-1(LL)P(26)-2(LL)) Nanocomplexes protected as much as 95% of the insulin against degradation by trypsin.

Colon-targeted delivery systems

Proteolytic enzymes in the stomach degrade insulin, but in intestines peptidase activity is low and drainage into lymph is maximized. Researchers are exploring colon-specific delivery for insulin. To achieve colon specific delivery of insulin, Hideyuki et al. prepared azopolymer-coated pellets containing fluorescein isothiocyanate dextran (FD-4) (45). In vitro drug-release experiments were carried out according to Japanese Pharmacopoeia XII (rotating basket method). The release of FD-4 from the pellets in phosphate buffered saline was very small. However, the release of FD-4 was markedly increased in the presence of rat ceacal contents. The pharmacodynamic studies of the azopolymer-coated pellets containing these peptides with camostat mesilate (protease inhibitor) were carried out by measuring the hypoglycemic effects. A slight decrease in plasma-glucose levels was observed following the oral administration of these pellets containing 12.5 IU of insulin compared with the same dose of insulin solution. The authors concluded that azopolymer-coated pellets with protease inhibitor might be useful carriers for the colon-specific delivery of insulin.

Yakugaku Zasshi developed two types of microcapsular devices containing new acrylate-based nanogels with a specific solute-permeability for the delayed- or thermosensitive-release of peptide drugs (46). A nanogel-particle of acrylic terpolymer, ethyl acrylate-methyl methacrylate-2-hydroxy-ethyl methacrylate, was newly synthesized by emulsion polymerization to construct delayed-release microcapsules. The insulin-loaded lactose particles were spray coated with the acrylic terpolymers. These microcapsules showed a pH-in-dependent delayed-release profile. Oral administration of the microcapsules with the lag time of 6 h to beagle dogs resulted in significantly reduced blood glucose concentration, leading to colon-specific insulin delivery with pharmacological availability of 5%. Meanwhile, poly(N-isopropylcarylamide) (p(NIPAAm)] nanogel-particles with a reversible temperature-dependent swelling property were prepared by dispersion polymerization to fabricate microcapsular membranes with thermosensitively changeable permeability. The microcapsules constructed by coating of drug-loaded CaCO3 particles with a blend mixture of the p(NIPAAm) nanogels and ethylcellulose pseudo-latex exhibited an on-off positively thermosensitive drug-release; the release rate was remarkably enhanced at higher temperatures possibly due to the formation of voids through the shrinkage of p(NIPAAm) nanogels in the membrane. A possible application of this type of microcapsules can be found in externally temperature-activated pulsatile peptide delivery.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here